Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Esperion Therapeutics Community
NasdaqGM:ESPR Community
1
Narratives
written by author
0
Comments
on narratives written by author
33
Fair Values set
on narratives written by author
Community Investing Ideas
Esperion Therapeutics
Popular
Undervalued
Overvalued
Esperion Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Rising Digital Adoption And Global Partnerships Will Shape Future Markets
Key Takeaways Growing adoption of cholesterol therapies, international partnerships, and improved patient access are expected to drive sustained revenue and margin growth. Extended patent protection and pipeline expansion reduce near-term risks and offer long-term growth opportunities through new treatment indications.
View narrative
US$5.80
FV
64.8% undervalued
intrinsic discount
18.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
5 days ago
author updated this narrative
Your Valuation for
ESPR
ESPR
Esperion Therapeutics
Your Fair Value
US$
Current Price
US$2.04
66.9% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-325m
536m
2015
2018
2021
2024
2025
2027
2030
Revenue US$536.2m
Earnings US$78.5m
Advanced
Set Fair Value